drugset / Trial / NCT02096341

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

NCT02096341

Phase 1 Terminated 2 enrolled EpicentRx, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To investigate the dosage of RRx-001 by the subcutaneous route.

Timeline

Start
2014-04
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NIBROZETONE Other / unclassified 16 mg/m2 Subcutaneous
Subject NIBROZETONE Other / unclassified 27 mg/m2 Subcutaneous

Indications